Data Licensing News
Who is buying AI training data, what they pay, and what the courts just did.Subscribe on Substack
DealsLicensingPayouts

Tempus and Recursion swap up to $84 million in optional fees for $42 million committed

The data license now runs through November 2029, and Tempus also licenses Recursion's TxFM RNA model.

Tempus AI said on September 21, 2026, that it had extended its data license agreement with Recursion Pharmaceuticals through November 2029.

Per the release, the parties replaced discretionary license fees potentially totaling $84 million over the next two years with committed payments totaling $42 million over the next three years.

Tempus also entered a new agreement to license Recursion's RNA foundation model, TxFM, on a non-exclusive, worldwide basis under a separate agreement.

Why it matters: this is a rare public look at how a data license gets repriced. The headline potential fell by half, but the money became committed rather than optional.

Sources

  1. Tempus AI investor release, Sept. 21, 2026

Spotted an error? See our corrections policy.

Related